"The Native Antigen Company, one of the world's leading suppliers of
reagents that enables research into vaccines and diagnostics for
emerging and endemic infectious diseases, today announced the
commercial introduction of its Novel Coronavirus antigens, derived
from the emerging Wuhan strain," it said in a statement.
"These recombinant proteins offer scientists high-quality reagents
to support ongoing infectious disease research, and the development
of diagnostics and vaccines," added the company.
(Reporting by Sudip Kar-Gupta, editing by Louise Heavens)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
|